Boston Scientific Corporation · NYSE:BSX
Boston Scientific — 2020 North American Neuromodulation Society (NANS) Annual Meeting
23 slides from Boston Scientific's conference presentation, January 2020
Slide 1: 2020 North American Neuromodulation Society Investor Update
2020 North American Neuromodulation Society Investor Update Maulik Nanavaty President and Senior Vice President, Neuromodulation Jesse Feinkind Vice President, Global Pain Milad Girgis Vice President, Global Brain Modulation
Slide 2: Safe Harbor for Forward-Looking Statements
Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,”
Slide 3: Financial & Regulatory Disclaimers
Financial & Regulatory Disclaimers Financial Disclaimers Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates. Non-GAAP Financial Measures: This presentation contains non-GAAP measures (denoted with *) in
Slide 4: Neuromodulation: Leading in pain therapies and brain modulation
Neuromodulation: Leading in pain therapies and brain modulation Exciting, highly underpenetrated and high-growth market Pain Therapies – Category leadership with innovative, evidenced-based platforms – Spectra WaveWriter™ SCS system, Vertiflex® procedure, and RF therapy – focused on personalizing th
Slide 5: Exciting, large and underpenetrated markets
Exciting, large and underpenetrated markets Pain Therapies Brain Modulation Spinal Cord RF DBS for Movement Vertiflex® Stim Ablation Disorders Return to Growth 10%+ Mkt Growth Untapped Mkt 10%+ Mkt Growth 3M+ with chronic 10M+ with severe 6M with moderate 1.2M with Parkinson’s neuropathic pain U.S.1
Slide 6: Pain Therapies: Category leadership with a winning, diverse, evidence-based portfolio
Pain Therapies: Category leadership with a winning, diverse, evidence-based portfolio 20+ ongoing clinical research Providing solutions for the evolving patient care continuum studies & RCTs1 COMBO RCT: Parallel-group RCT to demonstrate value of multiple modalities and combining mechanisms using Spe
Slide 7: Pain Therapies: Vertiflex procedure fills untapped therapy gap
Pain Therapies Vertiflex® procedure fills untapped therapy gap Accelerating physician access and training for treatment Vertiflex® Procedure: Superion® Indirect Decompression System of moderate Lumbar Spinal Stenosis (LSS) Seeing strong overall demand and increased utilization Synergies from phy
Slide 8: Pioneering neural dosing of sub-perception therapy
Pain Therapies Pioneering neural dosing of sub-perception therapy PROCO RCT1 The HALO Study2 Contour™ drives efficiency Effective pain relief 1,000 930 89% less 10 Charge-per-second (µC/s) 8.2 800 8 600 6 400 330 4 2.5 200 106 2 0 0 10 kHz 1 kHz 200 Hz w/ Baseline 200 Hz Contour w/ Contour Contour p
Slide 9: COMBO RCT: Combination therapy provides an unparalleled level of clinical success
Pain Therapies: COMBO RCT: Combination therapy provides an unparalleled level of clinical success 98% clinical success with WaveWriter combination therapy WaveWriter combination therapy has a higher at 3-month interval responder rate vs. monotherapy at 3 months 100% 98% 88% 100% 80% 88% 44% Up to 3
Slide 10: Redefining SCS: Better relief + more responders
Pain Therapies Redefining SCS: Better relief + more responders The SIMPLIFY METHOD™ Personalization Made Simple + mySCS™ A connected experience for patients Improved Trial Success1 % Patients With Successful Trial +6% 85% 91% without mySCS with mySCS N = 1265 N = 730 10
Slide 11: Transformative results from next gen innovative therapy
Pain Therapies Transformative results from next gen innovative therapy FAST™: Fast Acting Subperception Therapy Promising data; ongoing FAST study to corroborate early findings1 10 9 8.4 Response NRS Pain Score (0-10) 8 7 6 5 4 3 2 1.3 1.6 1 0 Baseline FAST 3 months N = 41 N = 41 N = 26 Time 11
Slide 12: Pain Therapies: The Future Is Now
Pain Therapies: The Future Is Now Beyond VAS to automated deep personalization NAVITAS/ENVISION1: Today: Next: Predictive therapy with deep 3 years of study endeavors Subjective pain analytics personalization Partnership with IBM Research Composite metrics Visual Analog Scale Study continuing Over
Slide 13: Brain Modulation: Large, underpenetrated Parkinson's population
Brain Modulation Large, underpenetrated Parkinson’s population1,2,3 REFERRAL PATHWAY U.S. PARKINSON’S PATIENT POPULATION COMMUNITY 1.2M Patients with General Practitioner Parkinson’s disease Community Neurologist Patients diagnosed and treated 1M (+60K newly diagnosed / year) Movement Disorder 240k
Slide 14: Brain Modulation: Meaningful innovation redefines the market
Brain Modulation Meaningful innovation redefines the market BSC DBS Patients Served Globally US Directional Worldwide leader in System directionality Launch #1 market share in Europe US entry Strong momentum in the US; #2 market share EU Directional System Launch Agile innovation: 3 systems in 7 yea
Slide 15: Brain Modulation: Innovation backed by strong clinical data
Brain Modulation Innovation backed by strong clinical data Next-Gen Platform and Programmer (2021/2022+) Next-Gen Programming with Visualization and Vercise™ Platform Vercise™ PC and Gevia™ Redefining patient outcomes STIMVIEW™XT (2020) Directional Systems Precision targeting with Most precise contr
Slide 16: Vercise Therapy: Differentiated patient outcomes
Brain Modulation Vercise™ Therapy: Differentiated patient outcomes 50 7 Improvement in ON time (hours) 37.4 6 Mean UPDRS III Scores (Meds Off) 40 5 30 4 20 15.0 3 6.0 13.5 13.7 5.0 2 4.4 4.0 10 3.1 1 0 0 2012 Okun 2010 Follett* 2006 Deuschl** 2013 INTREPID Baseline Week 12 Week 26 Week 52 (Abbott de
Slide 17: Vercise Therapy: Learning ecosystem that is dynamic by design
Brain Modulation: Vercise™ Therapy: Learning ecosystem that is dynamic by design today and for the future Predictive Brain Maps Brainlab® Directional Systems Visualization Smart Programming Advanced Surgical Cartesia™ directionality StimView™ XT Captures Outcomes Planning Clinical Data Personalizing
Slide 18: Brain Modulation: Indications beyond Movement Disorders
Brain Modulation Indications beyond Movement Disorders Alzheimer’s disease ($5B+) • VC investment in Functional Neuromodulation Stroke rehabilitation ($3B+) • Pilot study (42 patients) completed • VC investment in ENSPIRE • RCT initiated under IDE • Ongoing pilot study Clinical Research • Depression
Slide 19: Neuromodulation: Leading in pain therapies and brain modulation
Neuromodulation: Leading in pain therapies and brain modulation Exciting, highly underpenetrated and high-growth market Pain Therapies – Category leadership with innovative, evidenced-based platforms – Spectra WaveWriter™ SCS system, Vertiflex® procedure, and RF therapy – focused on personalizing th
Slide 20: Boston Scientific NANS 2020
Boston Scientific NANS 2020 Electronic Posters Podium Presentations Paper Poster Presentations (e-posters) Friday, January 24, 5:00PM – 7:00PM (Florentine Ballroom) Accessible Using the 2020 NANS Annual Meeting Smartphone App Exploration of High and Low Frequency Options for A Novel Sub-Perception S
Slide 21: Citations
Citations Slide 5 (Exciting, large, underpenetrated and high-growth markets): 1. Bennett GJ. Neuropathic pain: an overview. In: Borsook D, ed. Progress in Pain Research and Management. Vol. 9. Seattle, Wa: IASP Press; 1997:109–113. 2. CDC Journal Morbidity and Mortality Weekly Report 2014 3. Data on
Slide 22: Citations
Citations Slide 11 (Pain Therapies: Transformative results from next generation innovative therapy): 1. Metzger C, et al. A Novel Sub-Perception Spinal Cord Stimulation Therapy Enabling Clinically Significant Pain Relief and Fast Onset. NANS Annual Meeting. January 2020. Slide 12 (Pain Therapies: Th
Slide 23: Supplemental Non-GAAP Disclosures
Supplemental Non-GAAP Disclosures Less: Impact Less: Impact of of Recent Foreign Currency Operational Acquisitions / Organic FY 2019 Revenue Growth1 (unaudited) compared to FY 2018 Reported Basis Fluctuations Basis Divestitures Basis Neuromodulation 12% -1% 13% 6% 7% 1 Based on preliminary, unaudite
Boston Scientific — 2020 North American Neuromodulation Society (NANS) Annual Meeting on 6ix